Atossa Genetics Announces Issuance of Patent US9,052,318 by the U.S. Patent and Trademark for Breast Cancer Detection Using Absorbent Paper

SEATTLE, WA--(Jun 11, 2015) - Atossa Genetics Inc. (NASDAQ: ATOS), the Breast Health Company, announced today that the U.S. Patent and Trademark Office has issued a new patent, Serial No. 9,052,318, to Atossa, titled "Absorbent Paper and Uses Thereof for Breast Cancer Detection."

Dr. Steven Quay, Chairman, CEO & President of Atossa Genetics, said, "We are thrilled with the issuance of a U.S. patent for methods for identifying an individual's risk of developing breast cancer using absorbent paper to collect the individual's nipple aspirate fluid. Our patent estate now includes 147 issued patents and this particular patent is a big step forward in creating stockholder value and securing our proprietary rights to develop devices and tests that might one day be used to predict the risk of developing breast cancer based on the protein concentration and/or the number of cells, if any, in a breast fluid sample collected on an absorbent paper."

Resverlogix Reports on the Beneficial Effects of RVX-208 on Glucose Metabolism in Prediabetes Mellitus at the American Diabetes Association's (ADA) Scientific Sessions in Boston, MA

CALGARY, June 8, 2015  - Resverlogix Corp. (TSX:RVX.TO) today announced that findings of a study performed by the Baker IDI Heart and Diabetes Institute, Melbourne, Australia and Resverlogix's scientists were reported at the 2015 ADA Scientific Sessions in Boston, MA.  The presentation was entitled "Effects of the ApoA-I Inducer, RVX-208 on Glucose Metabolism in Individuals with Prediabetes Mellitus."  The data in the presentation was based on patients with prediabetes mellitus who already had abnormal blood glucose levels. Treatment with RVX-208 (200 mg/day) for 29-33 days led to not only a reduction in glucose absorption but also suppression of endogenous glucose production. The significance of these findings are as follows: (1) short duration of RVX-208 treatment had effects on glucose metabolism, and (2) both the reduction in glucose absorption and production are expected to be of benefit in patients with prediabetes mellitus.

Anthera Pharmaceuticals Announces Additional Data on Patient-Reported Outcomes From Phase 2b PEARL-SC Blisibimod Study

HAYWARD, Calif., June 4, 2015 -- Anthera Pharmaceuticals, Inc. (ANTH), a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs, today announced that additional data from its Phase 2b PEARL-SC study will be presented in a poster at the European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology in Rome, Italy.

As part of a guided poster tour on June 6^th, 2015, Dr. Michelle Petri, Director of the Hopkins Lupus Center at Johns Hopkins University, will present breaking data on the impact of treatment with blisibimod on patient-reported fatigue and improvement in disease biomarkers.